Stay updated on Risankizumab in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Risankizumab in Atopic Dermatitis Clinical Trial page.

Latest updates to the Risankizumab in Atopic Dermatitis Clinical Trial page
- CheckyesterdayChange DetectedRevision: v3.4.2 was added; the prior Notice about government funding lapse and Revision: v3.4.1 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check8 days agoChange DetectedAdded a government funding notice banner and updated the site revision from v3.4.0 to v3.4.1. These changes are cosmetic and do not alter the study content.SummaryDifference0.2%

- Check15 days agoChange DetectedMinor UI/text tweaks were made: a glossary display option, capitalization updates for QC-related fields and No FEAR Act data, and a new revision tag (v3.4.0). These edits do not affect study content, eligibility criteria, results, or user workflow.SummaryDifference0.1%

- Check29 days agoChange DetectedRevision history updated: added Revision v3.3.4 and removed Revision v3.3.3.SummaryDifference0.0%

- Check51 days agoChange DetectedLocations section updated: new sites across the US, Australia, and Canada were added and previous site entries were removed, altering the list of participating sites for the study. Revision: v3.3.3.SummaryDifference3%

- Check73 days agoChange DetectedRevision: v3.3.2 is now displayed, replacing v3.3.1 in the page footer; the change is cosmetic and does not affect the study content or user interactions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Risankizumab in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab in Atopic Dermatitis Clinical Trial page.